Skip to content
Search

Latest Stories

Physician and anaesthesia associates will soon be regulated by the GMC

Physician and anaesthesia associates will soon be regulated by the GMC

Regulation of medical associate professionals will improve patient safety and relieve pressure on doctors and GPs

The UK government will lay legislation today (13 December 2023) to allow the General Medical Council (GMC) to begin the process of regulating medical associates to expand their roles in the NHS.


This will support plans to reduce pressure on doctors and GPs and improve access for patients, the Department of Health and Social Care (DHSC) said.

Physician associates (PAs) and anaesthesia associates (AAs) will have the same levels of regulatory oversight and accountability as doctors and other regulated healthcare professionals once the regulations come into force, which is expected at the end of 2024.

The GMC will design and deliver detailed regulatory processes for registration, education, standards and fitness to practise for both professions.

Health Secretary, Victoria Atkins, said: "PAs and AAs are already making a great contribution to the NHS, supporting doctors to provide faster high-quality care for patients.

"This new legislation paves the way for these professionals to be held to the same strict standards as doctors, boosting patient safety.

“This is part of our Long-Term Workforce Plan to reform the NHS to ensure it has a workforce fit for the future.”

Currently, there are around 1,500 PAs working in hospitals and 1,700 in primary care settings, and approximately 320 AAs in the NHS.

The NHS Long Term Workforce Plan aims to increase the PA workforce to 10,000 by 2036-2037 and the AA workforce to 2,000 over the same period.

Dr Navina Evans, Chief Workforce, Training and Education Officer at NHS England, commented: “Physician and anaesthesia associates are an important part of clinical teams across the NHS, providing support to thousands of patients with the appropriate supervision every day, while freeing up time for other clinicians.

“Regulation of these internationally recognised roles will ensure the highest standards are met as thousands more are trained to do the role.”

The NHS is also targeting to near double medical school and nursing training places over the next 15 years.

In order that the public are able to clearly distinguish doctors and medical associates, the GMC is actively considering the format for the reference numbers that will have when they join the register.

GMC Chief Executive Charlie Massey said: “This is a welcome and significant milestone towards bringing PAs and AAs into regulation.

“We’re pleased to support the development of these valuable professionals recognising the important role they play in the medical workforce. Regulation will help increase the contribution PAs and AAs can make to UK healthcare while keeping patients safe.”

The DHSC has also published its full consultation response on regulating PAs and AAs.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less